The existing premium services 'Short-Term Investor’, 'Under The Radar - Small Stocks – Big Potential', and 'Emerging Biostocks - Investing in Biotech and Pharma' now under a single umbrella...‘RTT Intelligent Investor’. Absolutely free for a week! A brand new Macro Intelligence’ premium column packs more punch into the new service. Signing up also gives complimentary access to value-addons including research articles, Trending market/stock movers, Top stories of the day, news that impact stocks and markets, key upcoming Wall Street and other events, and much more.
Learn More
Biotechnology companies’ fortunes depend on binary events, such as FDA approvals and clinical trials results. Drugs, devices, etc. either work or fail – with huge implications for the stock price.
This volatility opens the door to big profits, particularly in the mid or small
cap part of the sector. However, capitalizing on these opportunities depends on
knowing when the key events are going to happen.
Given there are thousands of events that can impact biotech stocks, it is difficult
for individual investors and traders to keep track of all the potential regulatory
and clinical catalysts. This can result in easily missing out on some extraordinary
investment opportunities. This is where the RTT Biotech Stocks service can help
both novice and professional investors stay ahead of the markets.
RTT tracks and monitors hundreds of companies and potential market-moving events.
These include such things as pending new drug approvals, new FDA submissions, pending
mid/early-stage clinical trial results, late-stage phase 3 clinical trial results,
FDA advisory panel meetings and much more. The RTT Biotech Stock service alerts
users ahead of key events, enabling our subscribers to take advantage of the opportunities.
Sign
up today for your FREE 7 days trial, and let us help you find the best
biotech investment opportunities. This offer is 100% RISK-FREE. If you are satisfied
with the service after the 7 day trial, continue using the service at just $99/month.
Our premium service gives biotech investors the edge they need to make their investments
and trades more successful by discovering overlooked and undervalued pharmaceutical
and health-care opportunities long before they come to the attention of the general
investing public.
Although past performance is not indicative of future results, the average of all
biotech stocks we have profiled over the last two years have yielded an average
of 60% gains, with many yielding triple digit gains.
Here’s how some of our recent winners have fared:
-
VKTX was trading around $6.07 when we alerted our readers on February 5, 2018. The stock logged in a gain of 295% in 7 months.
-
CATS was trading around $4.92 when we alerted our readers on April 23, 2018. The stock touched a high of $14.29 on September 18, 2018, returning a maximum gain of 190%.
-
Our alert on SLDB was published on May 14, 2018 when it was trading around $22.46. The stock touched an all-time high of $54.83 on June 19, 2018, which equates to a gain of 144%.
-
We profiled CSBR on June 6, 2018 when it was trading around $5.66. The stock touched a high of $17.90 on September 28, 2018, in less than 4 months of our alert, reflecting a gain of 216%.
-
Another stock pick worth mentioning is AMRN. We alerted this stock to our readers on July 17, 2018, at around $2.79, and it touched a high of $23.34 on November 6, 2018, representing a gain of nearly 635%.
Check our complete performance to
see our track record.
With your subscription you will receive:
- Email alert whenever we publish a report on an upcoming event
- Access to all previous reports and comprehensive performance details
- Week ahead briefing - details of all the key events to look for in the week ahead